| Active substance |
Thymosin Alpha-1 |
| Also known as |
TA1, Thymalfasin |
| Blood pressure |
No significant impact |
| Chemical name |
L-serine, L-tyrosyl-L-glutaminyl-L-cysteinyl-L-glutaminyl-L-threonyl-L-seryl-L-cysteinyl-L-prolyl-L-seryl-L-lysyl-L-leucyl-L-glutaminyl-L-threonyl-L-leucyl-L-glutamyl-L-asparaginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-threonyl-L-lysyl-L-leucyl-L-lysyl-L-glutamyl-L-threonyl-L-asparaginyl-L-threonyl-L-argininamide |
| Dosage (medical) |
Typically 1.6 mg daily |
| Dosage (sports) |
Not officially sanctioned for sports use |
| Effects |
Enhanced immune response, increased activity of T-cells, modulation of cytokine production |
| FORM |
1 vial x 10 mg |
| Formula |
C129H215N33O55 |
| Half-life |
Approximately 2 minutes |
| Hepatotoxicity |
Minimal to none |
| Lab Test |
Immune response markers and T-cell counts |
| Main action |
Immune modulation |
| Side effects |
Local reactions at the injection site, possible systemic reactions like fever or fatigue |
| Storage conditions |
Store in a refrigerator at 2-8В°C |
| Substance class |
Peptide hormone |
| Trade name |
Zadaxin |
| Use in sports |
Not approved, potential use for immune support |
| Water Retention |
None |
| Manufacturer |
DEUS MEDICAL |
